臨床泌尿器科73巻10号

2019年09月発行

特集 腎移植臨床の進歩―集学的治療における泌尿器科医の役割を再考する

〈免疫抑制〉

ABO不適合腎移植―脱感作療法と免疫学的順応機構解明の最前線

著者： 田﨑正行¹

所属機関： ¹新潟大学大学院医歯学総合研究科腎泌尿器病態学分野

ページ範囲：P.736 - P.744

文献概要

▶ポイント

・ABO不適合腎移植において術前の脱感作療法は非常に重要である．

・脱感作療法の内容は患者ごとに個別化できる可能性が示唆される．

・免疫学的順応のメカニズムは，補体制御蛋白の変化と抗体産生の抑制機構が関与している可能性がある．

参考文献

1） Irei T, Ohdan H, Zhou W, et al : The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade : novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation. Blood 110 : 4567-4575, 2007

2） 大段秀樹 : Mycophenorate mofetil （セルセプト）. 移植48 : 333-338, 2013

3） 田中友加, 大段秀樹 : m-TOR阻害薬のT細胞・B細胞サブクラス別感受性解析. 今日の移植25 : 504-509, 2012

4） Haneda M, Owaki M, Kuzuya T, et al : Comparative analysis of drug action on B-cell proliferation and differentiation for mycophenolic acid, everolimus, and prednisolone. Transplantation 97 : 405-412, 2014

5） Takahashi K, Saito K, Takahara S, et al : Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 4 : 1089-1096, 2004

6） Shirakawa H, Ishida H, Shimizu T, et al : The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy : a single-center experience. Clin Transplant 25 : 878-884, 2011

7） Masterson R, Hughes P, Walker RG, et al : ABO incompatible renal transplantation without antibody removal using conventional immunosuppression alone. Am J Transplant 14 : 2807-2813, 2014

8） Barnett AN, Manook M, Nagendran M, et al : Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation. Transpl Int 27 : 187-196, 2014

9） Okada M, Watarai Y, Iwasaki K, et al : Favorable results in ABO-incompatible renal transplantation without B cell-targeted therapy : Advantages and disadvantages of rituximab pretreatment. Clin Transplant 31 ［Epub 2017 Aug 29］

10） Lee J, Lee JG, Kim S, et al : The effect of rituximab dose on infectious complications in ABO-incompatible kidney transplantation. Nephrol Dial Transplant 31 : 1013-1021, 2016

11） Lee KW, Park JB, Oh DK, et al : Short-Term Outcomes of ABO-Incompatible Living Donor Kidney Transplantation With Uniform Protocol : Significance of Baseline Anti-ABO Titer. Transplant Proc 48 : 820-826, 2016

12） Nakao T, Ushigome H, Kawai K, et al : Evaluation of rituximab dosage for ABO-incompatible living-donor kidney transplantation. Transplant Proc 47 : 644-648, 2015

13） Tasaki M, Yoshida Y, Miyamoto M, et al : Identification and characterization of major proteins carrying ABO blood group antigens in the human kidney. Transplantation 87 : 1125-1133, 2009

14） Takahashi K, Saito K, Nakagawa Y, et al : Mechanism of acute antibody-mediated rejection in ABO-incompatible kidney transplantation : which anti-A/anti-B antibodies are responsible, natural or de novo? Transplantation 89 : 635-637, 2010

15） Takahashi M, Saito K, Nakagawa Y, et al : Chapter 5. Is it really necessary to remove anti-A, anti-B antibodies. In ABO-Incompatible Kidney Transplantation? ABO-INCOMPATIBLE KIDNEY TRANSPLANTATION. pp67-75, Elsevier, Amsterdam, 2015

16） Krishnan N, Coates R, Daga S, et al : ABO-incompatible renal transplantation without antibody removal using conventional immunosuppression alone. Am J Transplant 15 : 1728-1729, 2015

17） Tasaki M, Nakajima T, Imai N, et al : Detection of allogeneic blood group A and B enzyme activities in patients with ABO incompatible kidney transplantation. Glycobiology 20 : 1251-1258, 2010

18） Iwasaki K, Miwa Y, Ogawa H, et al : Comparative study on signal transduction in endothelial cells after anti-a/b and human leukocyte antigen antibody reaction : implication of accommodation. Transplantation 93 : 390-397, 2012

19） Tasaki M, Saito K, Nakagawa Y, et al : Acquired Downregulation of Donor-Specific Antibody Production After ABO-Incompatible Kidney Transplantation. Am J Transplant 17 : 115-128, 2017